Hearing Vistagen Therapeutics Upgraded From A Hold To A Buy At Jefferies; Price Target $15
Portfolio Pulse from Charles Gross
Jefferies has upgraded Vistagen Therapeutics from a 'Hold' to a 'Buy' and set a price target of $15.

December 07, 2023 | 12:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen Therapeutics has been upgraded by Jefferies from 'Hold' to 'Buy' with a new price target of $15, indicating a positive outlook on the stock.
Analyst upgrades typically lead to a positive short-term reaction in a stock's price as they suggest a better-than-expected future performance. The upgrade from 'Hold' to 'Buy' and the significant price target of $15 by Jefferies for Vistagen Therapeutics is likely to be viewed favorably by investors, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100